Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
Umeda Y, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Onuma T, Kuwatsuka Y, Fujimoto N, Kaneko T, Onishi M, Namikawa K, Yamazaki N, Nakamura Y. Umeda Y, et al. Among authors: kuwatsuka y. Eur J Cancer. 2021 Nov;157:361-372. doi: 10.1016/j.ejca.2021.08.034. Epub 2021 Sep 23. Eur J Cancer. 2021. PMID: 34563991
Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used.
Ogata D, Namikawa K, Otsuka M, Asai J, Kato H, Yasuda M, Maekawa T, Fujimura T, Kato J, Takenouchi T, Nagase K, Kawaguchi M, Kaji T, Kuwatsuka Y, Shibayama Y, Takai T, Okumura M, Kambayashi Y, Yoshikawa S, Yamazaki N, Tsuchida T. Ogata D, et al. Among authors: kuwatsuka y. Eur J Cancer. 2020 Mar;127:108-117. doi: 10.1016/j.ejca.2019.12.018. Epub 2020 Jan 28. Eur J Cancer. 2020. PMID: 32004792
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, Yamazaki N. Nakamura Y, et al. Among authors: kuwatsuka y. ESMO Open. 2021 Dec;6(6):100325. doi: 10.1016/j.esmoop.2021.100325. Epub 2021 Nov 25. ESMO Open. 2021. PMID: 34839104 Free PMC article.
Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.
Nakamura Y, Namikawa K, Kiniwa Y, Kato H, Yamasaki O, Yoshikawa S, Maekawa T, Matsushita S, Takenouchi T, Inozume T, Nakai Y, Fukushima S, Saito S, Otsuka A, Fujimoto N, Isei T, Baba N, Matsuya T, Tanaka R, Kaneko T, Onishi M, Kuwatsuka Y, Nagase K, Onuma T, Nomura M, Umeda Y, Yamazaki N. Nakamura Y, et al. Among authors: kuwatsuka y. Eur J Cancer. 2022 Nov;176:78-87. doi: 10.1016/j.ejca.2022.08.030. Epub 2022 Oct 1. Eur J Cancer. 2022. PMID: 36194906
Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients.
Mori T, Namikawa K, Yamazaki N, Kiniwa Y, Yamasaki O, Yoshikawa S, Inozume T, Kato H, Nakai Y, Fukushima S, Takenouchi T, Maekawa T, Matsushita S, Otsuka A, Nomura M, Baba N, Isei T, Saito S, Fujimoto N, Tanaka R, Kaneko T, Kuwatsuka Y, Matsuya T, Nagase K, Onishi M, Onuma T, Nakamura Y. Mori T, et al. Among authors: kuwatsuka y. Front Med (Lausanne). 2023 Aug 10;10:1229937. doi: 10.3389/fmed.2023.1229937. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37636577 Free PMC article.
135 results